Merck

BCL-x

Cancer letters (2017-09-28)
Sara Fatima Faqar-Uz-Zaman, Ulrike Heinicke, Michael Torsten Meister, Meike Vogler, Simone Fulda
ABSTRACT

BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-x

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
テトラメチルローダミンメチルエステルパークロレート, ≥95%